BIO-RAD LABORATORIES-A (BIO) Forecast, Price Target & Analyst Ratings

NYSE:BIO • US0905722072

Current stock price

276.53 USD
+2.93 (+1.07%)
At close:
276.53 USD
0 (0%)
After Hours:

Analyst forecast overview

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for BIO-RAD LABORATORIES-A (BIO).

Forecast Snapshot

Consensus Price Target

Price Target
$341.70
+ 23.57% Upside
→ Price target details

Next Earnings Forecast

Earnings Estimate
Release Date
Apr 29, 2026
Period
Q1 / 2026
EPS Estimate
$1.87
Revenue Estimate
593.74M
→ Full earnings forecast details

ChartMill Buy Consensus

Rating
76.00%
Weighted Analyst Rating Score
→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target
$341.70
Upside
+ 23.57%
From current price of $276.53 to mean target of $341.70, Based on 10 analyst forecasts
Low
$282.80
Median
$341.70
High
$393.75

Price Target Revisions

1 Month
-5.63%
3 Months
-5.63%

Price Target Summary

10 Wall Street analysts provided a forecast for the next 12 months for BIO. The average price target is 341.7 USD. This implies a price increase of 23.57% is expected in the next year compared to the current price of 276.53.
The average price target has been revised downward by 5.63% in the past 3 months.
→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

BIO Current Analyst RatingBIO Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 0 0 0 0 0

Analyst Ratings History

BIO Historical Analyst RatingsBIO Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -19 -17 -15 -13 -11 -9 -7 -5 -3 -1 2 4 6 8 10

Analyst Ratings Consensus

ChartMill Buy Consensus
76.00%
BIO was analyzed by 10 analysts. The buy percentage consensus is at 76. So analysts seem to be have mildly positive about BIO.
In the previous month the buy percentage consensus was at a similar level.
BIO was analyzed by 10 analysts. More opinions would make the average more meaningful.
→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

DateFirmActionFrom → To
2025-10-30Wells FargoMaintains Equal-Weight -> Equal-Weight
2025-10-30CitigroupMaintains Buy -> Buy
2025-08-01RBC CapitalMaintains Outperform -> Outperform
2025-08-01Wells FargoMaintains Equal-Weight -> Equal-Weight
2025-06-09Wells FargoMaintains Equal-Weight -> Equal-Weight
2025-05-02UBSMaintains Buy -> Buy
2025-05-02RBC CapitalMaintains Outperform -> Outperform
2025-05-02CitigroupMaintains Buy -> Buy
2025-04-17Wells FargoMaintains Equal-Weight -> Equal-Weight
2025-02-12Wells FargoMaintains Equal-Weight -> Equal-Weight
2025-01-14RBC CapitalReiterate Outperform -> Outperform
2024-12-09RBC CapitalMaintains Outperform -> Outperform
2024-10-31RBC CapitalMaintains Outperform -> Outperform
2024-10-31CitigroupMaintains Buy -> Buy
2024-10-01CitigroupUpgrade Neutral -> Buy
2024-08-27Wells FargoInitiate Equal-Weight
2024-08-16RBC CapitalReiterate Outperform -> Outperform
2024-08-02RBC CapitalMaintains Outperform -> Outperform
2024-08-02CitigroupMaintains Neutral -> Neutral
2024-05-08UBSMaintains Buy -> Buy
2024-04-03CitigroupDowngrade Buy -> Neutral
2024-02-16UBSMaintains Buy -> Buy
2024-02-16RBC CapitalMaintains Outperform -> Outperform
2023-12-07UBSInitiate Buy
2023-08-07Wells FargoMaintains Overweight -> Overweight

Next Earnings Forecast Details

Next Earnings Details

Release Date
Apr 29, 2026
Period
Q1 / 2026
EPS Estimate
$1.87
Revenue Estimate
593.74M
Revenue Q2Q
1.42%
EPS Q2Q
-26.34%
Number of Analysts
6

Next Earnings Revisions

Revenue (1 Month)
0.38%
Revenue (3 Months)
-2.22%
EPS (1 Month)
-6.43%
EPS (3 Months)
-26.33%

Next Earnings Summary

BIO is expected to report earnings on 4/29/2026. The consensus EPS estimate for the next earnings is 1.87 USD and the consensus revenue estimate is 593.74M USD.
The next earnings revenue estimate has been revised downward by 2.22% in the past 3 months.
→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates 2026 - 2030

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

2023 2024 2025 2026 2027 2028 2029 2030
Revenue
YoY % growth
BIO revenue by date.BIO revenue by date.
2.671B
-4.67%		2.567B
-3.92%		2.583B
0.65%		2.654B
2.74%		2.735B
3.05%		2.806B
2.60%		2.853B
1.67%		2.949B
3.36%
EBITDA
YoY % growth
BIO ebitda by date.BIO ebitda by date.
N/A
-19.14%		N/A
-8.95%		N/A
-3.93%		457.38M
0.66%		489.36M
6.99%		501.54M
2.49%		480.76M
-4.14%		496.92M
3.36%
EBIT
YoY % growth
BIO ebit by date.BIO ebit by date.
365.696M
-24.88%		298.5M
-18.37%		266.1M
-10.85%		316.72M
19.02%		347.89M
9.84%		362.1M
4.08%		N/AN/A
Operating Margin
BIO operating margin by date.BIO operating margin by date.
13.69%11.63%10.30%11.93%12.72%12.90%N/AN/A
EPS
YoY % growth
BIO eps by date.BIO eps by date.
11.77
-17.29%		10.31
-12.40%		9.92
-3.78%		10.37
4.57%		11.48
10.68%		12.19
6.17%		9.84
-19.30%		10.21
3.80%

All data in USD

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

Q1 / 26 Q2 / 26 Q3 / 26 Q4 / 26 Q1 / 27 Q2 / 27 Q3 / 27 Q4 / 27
EPS
Q2Q % growth		1.87
-26.34%		2.55
-2.27%		2.59
14.57%		2.92
16.22%		3.06
63.29%		3.01
18.19%		2.94
13.70%		3.24
11.14%
Revenue
Q2Q % growth		593.74M
1.42%		664.85M
2.03%		678.27M
3.87%		723.64M
4.39%		641.59M
8.06%		704.48M
5.96%		696.02M
2.62%		759.27M
4.92%
EBITDA
Q2Q % growth		80.334M
-4.31%		119.21M
25.68%		124.91M
22.16%		135.71M
6.62%		124.51M
54.99%		142.93M
19.90%		134.97M
8.05%		147.06M
8.36%
EBIT
Q2Q % growth		44.355M
-22.05%		83.162M
4.61%		86.737M
27.93%		99.694M
61.06%		85.921M
93.71%		104.37M
25.50%		96.824M
11.63%		108.71M
9.04%

All data in USD

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

BIO Yearly Revenue VS EstimatesBIO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 500M 1B 1.5B 2B 2.5B
BIO Yearly EPS VS EstimatesBIO Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 5 10 15

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year
7.11%
EPS Next 5 Year
0.58%

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year
2.56%
Revenue Next 5 Year
2.54%

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year
17.21%
EBIT Next 5 Year
9.79%
→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

BIO-RAD LABORATORIES-A / BIO Forecast FAQ

Can you provide the average price target for BIO-RAD LABORATORIES-A stock?

10 analysts have analysed BIO and the average price target is 341.7 USD. This implies a price increase of 23.57% is expected in the next year compared to the current price of 276.53.

Can you provide the upcoming earnings date for BIO-RAD LABORATORIES-A?

BIO-RAD LABORATORIES-A (BIO) will report earnings on 2026-04-29, after the market close.

What are the consensus estimates for BIO stock next earnings?

The consensus EPS estimate for the next earnings of BIO-RAD LABORATORIES-A (BIO) is 1.87 USD and the consensus revenue estimate is 593.74M USD.

What is the consensus rating for BIO stock?

The consensus rating for BIO-RAD LABORATORIES-A (BIO) is 76 / 100 . This indicates that analysts generally have a positive outlook on the stock.